Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

Core Insights - Vaxcyte, Inc. has appointed Dr. Olivier Brandicourt, former CEO of Sanofi S.A., to its Board of Directors, enhancing its leadership with significant biopharmaceutical expertise [1][2] - Dr. Brandicourt's experience in the global vaccine market is expected to be instrumental as Vaxcyte advances its pneumococcal conjugate vaccine (PCV) candidates towards potential commercialization [2] - Vaxcyte is focused on developing high-fidelity vaccines to combat bacterial diseases, with its lead candidates VAX-31 and VAX-24 targeting invasive pneumococcal disease [6][8] Company Overview - Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines aimed at preventing bacterial diseases [6] - The company is developing broad-spectrum conjugate and novel protein vaccines, including VAX-31, a 31-valent PCV candidate, and VAX-24, a 24-valent PCV candidate [6][8] - Vaxcyte utilizes modern synthetic techniques and the XpressCF™ cell-free protein synthesis platform to produce complex vaccines efficiently [7] Leadership Background - Dr. Brandicourt has a distinguished career in the biopharmaceutical industry, previously serving as CEO of Sanofi S.A. and Bayer HealthCare AG, and has extensive experience at Pfizer [3][4] - His leadership roles have included advancing vaccine portfolios and strategic insights in commercial execution within the vaccine market [2][4] Strategic Goals - Vaxcyte aims to set a new standard of care in the prevention of invasive pneumococcal disease and contribute to combating antimicrobial resistance [2][6] - The company is committed to addressing unmet needs in bacterial disease prevention through its innovative vaccine candidates [2][8]